Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

詳細情報 詳細情報について

• CRID

  1361137045468784640

• DOI

  10.1016/s1470-2045(18)30497-2

• ISSN

  14702045

• Web Site

  https://api.elsevier.com/content/article/PII:S1470204518304972?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S1470204518304972?httpAccept=text/plain

• データソース種別

  • Crossref